anti-mutated KRAS antibody (Oblique Therapeutics)

N/A

Report date: 2025/03/18 18:06:20

Base Information

Drug Nameanti-mutated KRAS antibody (Oblique Therapeutics)
Drug Alias NameaKRAS antibody (Oblique Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsLung NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOblique Therapeutics AB
China Registration ClassN/A

Develop Information

Active CompaniesOblique Therapeutics AB
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A